- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting FGFR in Squamous Cell Carcinoma of the Lung
Authors
Keywords
-
Journal
Targeted Oncology
Volume 12, Issue 6, Pages 741-755
Publisher
Springer Nature
Online
2017-07-07
DOI
10.1007/s11523-017-0513-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial
- (2016) Nasser H. Hanna et al. LUNG CANCER
- Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation
- (2016) K. N. Nelson et al. MOLECULAR CANCER RESEARCH
- A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors
- (2015) A. W. Tolcher et al. ANNALS OF ONCOLOGY
- Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer
- (2015) Haruko Daga et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- FGFR as potential target in the treatment of squamous non small cell lung cancer
- (2015) Marcello Tiseo et al. CANCER TREATMENT REVIEWS
- Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)
- (2015) Mary E.R. O’Brien et al. EUROPEAN JOURNAL OF CANCER
- Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
- (2015) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- FGFR1 amplification in lung squamous cell carcinoma: A systematic review with meta-analysis
- (2015) Tao Jiang et al. LUNG CANCER
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
- (2014) J.- C. Soria et al. ANNALS OF ONCOLOGY
- Identification of Recurrent FGFR3-TACC3 Fusion Oncogenes from Lung Adenocarcinoma
- (2014) M. Capelletti et al. CLINICAL CANCER RESEARCH
- FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non-Small Cell Lung Cancer
- (2014) R. Wang et al. CLINICAL CANCER RESEARCH
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
- (2014) Martin Reck et al. LANCET ONCOLOGY
- A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors
- (2014) K. L. Kendra et al. MOLECULAR CANCER THERAPEUTICS
- Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
- (2013) R. Dienstmann et al. ANNALS OF ONCOLOGY
- Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer
- (2013) M Nishio et al. BRITISH JOURNAL OF CANCER
- Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma
- (2013) R. G. Liao et al. CANCER RESEARCH
- Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29
- (2013) S.A. Laurie et al. EUROPEAN JOURNAL OF CANCER
- Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients
- (2013) Youngwook Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer
- (2013) T. C. Harding et al. Science Translational Medicine
- Identification of Targetable FGFR Gene Fusions in Diverse Cancers
- (2013) Yi-Mi Wu et al. Cancer Discovery
- A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer
- (2012) R. C. Doebele et al. ANNALS OF ONCOLOGY
- Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment
- (2012) Carla M.L. van Herpen et al. ANTI-CANCER DRUGS
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
- (2012) D S Boss et al. BRITISH JOURNAL OF CANCER
- AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
- (2012) P. R. Gavine et al. CANCER RESEARCH
- Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
- (2012) A. N. Brooks et al. CLINICAL CANCER RESEARCH
- Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non-Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models
- (2012) J. Zhang et al. CLINICAL CANCER RESEARCH
- Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations
- (2012) N. Rekhtman et al. CLINICAL CANCER RESEARCH
- AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activityviatargeting VEGFR, FGFR and PDGFR
- (2012) Yuanfeng Zhou et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Genetic Changes in Squamous Cell Lung Cancer: A Review
- (2012) Rebecca S. Heist et al. Journal of Thoracic Oncology
- A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group Study N0528
- (2012) Grace K. Dy et al. Journal of Thoracic Oncology
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy
- (2012) Alexander Drilon et al. LANCET ONCOLOGY
- Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer
- (2012) Hans-Ulrich Schildhaus et al. MODERN PATHOLOGY
- Phase I Study of Pazopanib in Combination with Paclitaxel and Carboplatin Given Every 21 Days in Patients with Advanced Solid Tumors
- (2012) H. A. Burris et al. MOLECULAR CANCER THERAPEUTICS
- Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
- (2012) J. M. Gozgit et al. MOLECULAR CANCER THERAPEUTICS
- FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
- (2012) V. Guagnano et al. Cancer Discovery
- A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
- (2011) M. Reck et al. ANNALS OF ONCOLOGY
- Fibroblast growth factors and their receptors in cancer
- (2011) Jørgen Wesche et al. BIOCHEMICAL JOURNAL
- E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
- (2011) Ezia Bello et al. CANCER RESEARCH
- Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis
- (2011) C. Lieu et al. CLINICAL CANCER RESEARCH
- Pathology of Lung Cancer
- (2011) William D. Travis CLINICS IN CHEST MEDICINE
- Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase
- (2011) Vito Guagnano et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models
- (2011) G. Zhao et al. MOLECULAR CANCER THERAPEUTICS
- Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
- (2011) Amit Dutt et al. PLoS One
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- (2011) Peter S. Hammerman et al. Cancer Discovery
- A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
- (2010) D. J. Jonker et al. ANNALS OF ONCOLOGY
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients
- (2010) P. M. Ellis et al. CLINICAL CANCER RESEARCH
- Metabolism, Excretion, and Pharmacokinetics of Oral Brivanib in Patients with Advanced or Metastatic Solid Tumors
- (2010) T. Mekhail et al. DRUG METABOLISM AND DISPOSITION
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study
- (2010) Patricia LoRusso et al. INVESTIGATIONAL NEW DRUGS
- Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non–Small-Cell Lung Cancer
- (2010) Nasser Altorki et al. JOURNAL OF CLINICAL ONCOLOGY
- Roles of Fibroblast Growth Factor Receptors in Carcinogenesis
- (2010) E. M. Haugsten et al. MOLECULAR CANCER RESEARCH
- Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
- (2010) I. Okamoto et al. MOLECULAR CANCER THERAPEUTICS
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- (2010) J. Weiss et al. Science Translational Medicine
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors
- (2009) K. Mross et al. CLINICAL CANCER RESEARCH
- Phase I Trial of Pazopanib in Patients with Advanced Cancer
- (2009) H. I. Hurwitz et al. CLINICAL CANCER RESEARCH
- Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
- (2009) Jing Qing et al. JOURNAL OF CLINICAL INVESTIGATION
- Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
- (2009) Glenwood D. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas
- (2009) Adam J Bass et al. NATURE GENETICS
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
- (2008) H. Huynh et al. CLINICAL CANCER RESEARCH
- Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase
- (2008) J. Matsui et al. CLINICAL CANCER RESEARCH
- Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group
- (2008) Scott A. Laurie et al. JOURNAL OF CLINICAL ONCOLOGY
- Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
- (2008) Hendrik Fischer et al. MOLECULAR CANCER THERAPEUTICS
- Drug-sensitive FGFR2 mutations in endometrial carcinoma
- (2008) A. Dutt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search